30 results about "Obesity resistant" patented technology

A system and method are provided for a physically active game whose underlying purpose is to increase the level of physical activity in adolescents, and to have the game and associated activity be enjoyable and engaging such that physical activity becomes engrained as a habit that counters obesity. The game system includes a set of networked game modules that players touch in a sequence as prescribed by a game logic The correct module to touch next in the sequence is indicated by a notifier, such as a light turning on or an audible signal emitting from the module. Sensors on the modules transmit a signal to a controller which activates transmission of the next module in the sequence to activate a notifier element. Game data may be used to compute a score and be applied to game statistics. Data from the game may be transmitted to a remote server for storage, transformation into comparative data, and displayed on a web page.

The present invention relates to a Akkermansia muciniphila SNUG-61027 strain (accession number KCTC 13530BP) and a use thereof. Specifically provided are: a composition for appetite control or prevention, improvement, alleviation or treatment of metabolic diseases, containing, as an active ingredient, the strain, a culture liquid thereof and the like, or a B2UM07 protein isolated therefrom; a use of the composition for appetite control or prevention, improvement, alleviation and treatment of metabolic diseases; and a method for appetite control or prevention, improvement, alleviation and treatment of metabolic diseases by using the composition. Therefore, the present invention exhibits effects of weight loss and glucose homeostasis control, from among anti-obesity effects, and influence on brown fat and secretion of an appetite control hormone secretion.

The present invention relates to a pharmaceutical composition for the prevention and treatment of diabetes or obesity comprising as active ingredients a compound which inhibits the activity of dipeptidyl peptidase-IV (DPP-IV), a pharmaceutically acceptable salt thereof, a hydrate thereof, or a solvate thereof, and one or more other antidiabetic or antiobesity agents. The pharmaceutical composition exhibits excellent glucose tolerance and may be useful in the prevention and treatment of diabetes, obesity, and the like by effectively inhibiting blood glucose levels and reducing fat mass.

The invention discloses a soybean peptide solid beverage for preventing cold and provides a formula and a preparation method. The formula mainly comprises soybean peptide powder and multivitamins; raw materials are mixed and bagged and are subjected to metal impurity detection. The soybean peptide solid beverage disclosed by the invention not only has blood-lipid-lowering, easy-to-digest, easy-to-absorb, energy-metabolism-accelerating and anti-obesity effects of a soybean peptide product, but also has a plurality of physiological functions of eliminating fatigue, enhancing muscle stretching, resisting allergy and the like; the multivitamins, especially vitamin C and vitamin B groups, are added, so that the soybean peptide solid beverage has the effects of enhancing the immunity of organisms and improving the resisting capability on the cold; the soybean peptide solid beverage is suitable for people with different ages to drink; a production process is simple, sanitary and safe and the production cost is low, so that the soybean peptide solid beverage is suitable for large-scale popularization and generalization.

Disclosed are a functionally reinforced desalted nutritional composition, a desalted extract and a cold-water-extracted salt substitute, which are derived from halophytes that grow in coastal regions under highly saline conditions and thus retain high salt concentrations, as well as the use of the desalted nutritional composition for combating obesity. More particularly, this invention relates to a functionally reinforced desalted nutritional composition, a desalted extract and a salt substitute cold-water-extracted from halophytes that inhabit extreme environments of high salinity under high salt stress, the halophytes being desalted through a cold water extraction process at a low temperature based on the difference in water solubility of salts with change in temperature to allow only sodium chloride to be selectively removed, and the composition thus having decreased sodium content as well as having increased content of useful minerals such as potassium, as well as nutrients and physiologically active substances, which are naturally contained in halophytes.

The invention discloses a method for constructing a genetic engineering cell strain of an obesity-resistant medicine target point UCP1, and besides, discloses establishing and application of an obesity-resistant medicine high-flux screening model. Mainly a CRISPR / Cas9 system is related and utilized, two unique sgRNAs are designed, luciferase-T2A-tdTomato-WPRE-pA is knocked in after N end ATG of aUCP1 gene of cells, particularly luciferase and tdTomato are knocked in gene sites of immortalization brown fat cells UCP1, a first stably-transfected brown fat cell strain in which luciferase and tdTomato are inserted in a promoter region of the UCP1 is formed, and the first stably-transfected brown fat cell strain is applied to high-flux screening of obesity-resistant medicines, evaluation of the obesity-resistant medicines, evaluation of obesity-resistant active substances of organisms and development of a UCP1 detection reagent kit. The UCP1 is uncoupling protein specifically expressed atbrown fat tissue, and is an obesity-resistant new target point. The construction of the stably-transfected genetic engineering cell strain has important significance in the aspects of applying reportgenes and a high-connotation method, performing high-flux screening on a compound library acutely, accurately and efficiently, and obtaining obesity-resistant medicines capable of promoting thermogenesis and reducing weight.

Compositions, foods, and beverages which contain a salt-free or a reduced-salt fermented soybean paste-like food material in which the salt content is 5% or less, obtained by hydrolyzing soybean by a koji mold have an excellent anti-obesity action.

The invention discloses an application of oleanolic acid in preparation of medicine for treating obesity. According to the invention, the oleanolic acid enables in-vitro activation of TGR5, so that mice weight is controlled and high blood sugar can be reduced, and TGR5 can adjust stable state of bile acid and energy metabolism. The experiment shows that the TGR5 as a main acceptor (not the only acceptor) of a natural compound oleanolic acid (OA) has effect for resisting obesity and reducing blood sugar. The oleanolic acid (OA) can reduce the accumulation of wild-type mice body fat, but the effect can not be embodied on TGR5 mice; the result clearly indicates that TGR5 can adjust fat-reducing effect induced by OA; the oleanolic acid (OA) has slight efficacy to TGR5, because that OA has slight activation effect to FXR or other protein.

An amide derivative represented by the following formula: wherein the ring B is a heteroaryl group; X is a bond or a lower alkylene group; and R is a hydrogen atom, a halogen atom, a lower alkyl group, an amino group, an aryl lower alkyl group or a haloaryl lower alkyl group, or a salt thereof, is disclosed. A therapeutic agent for diabetes mellitus having both an insulin secretion promoting action and an insulin sensitivity potentiating action and also having anti-obesity and anti-hyperlipemia actions due to a selective stimulating action to beta3-receptors, is also disclosed.

The present invention relates to a novel Bifidobacterium longum or Lactobacillus rhamnosus strain having an effect of preventing or treating obesity, and a use thereof. Treatment of each of the lactic acid bacteria strains of Bifidobacterium longum and Lactobacillus rhamnosus, of the present invention, causes browning of white adipocytes and, particularly, it has been confirmed that beige adipocyte- and brown adipocyte-specific gene expression significantly increases over that of an untreated control group. In addition, as a result of experimentation on high fat diet-induced obese mice is carried out, each strain exhibits a weight gain inhibitory effect more significant than that of a negative control group, and an effect of increased expression of a thermogenesis-specific gene, in the white adipocytes of the mice, has been confirmed. Therefore, each of the lactic acid bacteria strains of Bifidobacterium longum and Lactobacillus rhamnosus exhibits an anti-obesity effect so as to be effectively usable as a food, a drug or a feed for preventing or treating obesity, thereby being very useful in related industries.

The present invention provides pharmaceutical compositions containing benzene compound(s) represented by General Formula (1) below and, particularly, LPL-activating compositions for use in hyperlipidemia therapeutic and preventive agents, anti-obesity agents, and the like:wherein R1, R2, R3 and R4 are as defined in the specification.

Described herein are inhibitors Transient Receptor Potential Canonical (TRPC) ion channels comprising TRPC4 protein and / or TRPC5 protein for use in combating obesity and other medical conditions including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.

The invention relates to the field of medicine health, in particular to a medicine composition with a weight reducing effect. The medicine composition is formed by combining polyunsaturated fatty acids and black tea extracts. The polyunsaturated fatty acids and the black tea extracts are used as main active ingredients; and the effects of various polyunsaturated fatty acids and the black tea extracts in the aspects of reducing fat and losing weight are integrated. Experiments prove that the composition provided by the invention has the advantages that the fat content of an experiment animal body can be obviously reduced; the obesity development is effectively controlled; and the obvious obesity-resistant effect is achieved. The composition provided by the invention completely uses ingredients from natural animals and plants as active ingredients; the advantages of wide material resources, low production cost, high safety, high efficiency, no dependence and no toxic or side effect after the long-time taking and the like are realized; and the medicine composition is suitable to be popularized and applied in a large range.

The invention belongs to the field of biomedicine, and relates to medical application of miR-574-5p, in particular to application of the miR-574-5p to preparation of drugs for preventing or treating diabetes and related diseases thereof. The invention provides application of the miR-574-5p and a recombinant vector or a recombinant cell for expressing miR-574-5p nucleic acid molecules to preparation of the drugs for preventing or treating the diabetes and the related diseases thereof. The invention also provides application of a reagent for detecting the miR-574-5p or an active expression levelof the miR-574-5p in serum or plasma to preparation of a kit for predicting and / or evaluating the treatment effect and prognosis of the diabetes and the related diseases thereof. Experiments prove that the miR-574-5p is highly expressed in human adipose tissues, and the expression quantity is remarkably increased along with adipose cell differentiation; the miR-574-5p is increased to promote adipose cell differentiation and resist insulin resistance caused by obesity; the phenomena of the obesity and the insulin resistance can be aggravated by inhibiting the miR-574-5p expression; and in people with similar BMI, the miR-574-5p expression in serum of people with abnormal glucose tolerance and the diabetes can be obviously reduced. The miR-574-5p can be used for detecting, preventing or treating the diabetes and the related diseases.

The invention relates to medical application of long-chain non-coding RNA (LncRNA-266), in particular to application of LncRNA-266 in preparation of a drug for inducing brown adipose cell differentiation, which can promote body energy consumption and resist obesity. Obese mice are treated by the LncRNA-266, and a result shows that the LncRNA-266 can promote differentiation of beige fat cells of the obese mice to brown fat cells and consume body energy, so that weight gain is inhibited. It is further found that the LncRNA-266 can reduce the blood glucose level of obese mice and improve the insulin sensitivity.

The invention relates to the technical field of liquid beverages, in particular to a liquid beverage capable of promoting fuel fat discharge, resisting fat and wrapping oil and capable of generating a warm feeling after being taken. The black ginger mask is prepared from the following raw materials: a black ginger extracting solution, fish collagen peptide, sodium hyaluronate, gamma-aminobutyric acid, an antioxidant anti-aging whitening agent, nicotinamide and the balance of compound fruit juice, according to the liquid beverage capable of promoting emission, burning fat, blocking fat and wrapping oil and generating warm feeling after being taken, the black ginger extracting solution is added and mixed with the compound fruit juice, so that the fruit juice has the effects of resisting obesity and metabolic syndrome, can promote burning of saccharides and fat in the body and generate energy, can provide vitality for the human body while resisting obesity, and plays a role in resisting fatigue; and the added antioxidant and anti-aging whitening agent can improve the elasticity of the skin of the human body, resist sugar, whiten the skin, enhance the immunity and resist fatigue.

The invention discloses application of blended edible oil compounded of sunflower seed oil and lard in the aspect of obesity resistance. The blended edible oil is prepared by compounding sunflower seed oil and lard, as well as adding 1wt% of caprin; and the prepared blended edible oil compounded of the sunflower seed oil and the lard is for daily consumption use. The blended edible oil compoundedof the sunflower seed oil and the lard disclosed by the invention is simple in proportion, low in cost and good in compatibility; being taken at an intake amount of 25-50 grams per person per day, theblended edible oil is capable of preventing hepatic adipose infiltration and improving lipid metabolism after long-term consumption, thereby achieving the functions of effectively reducing body weight, body fat ratio, fat cell volume, hepatic TG deposition and the like.

Provided is a composition for preventing, improving or treating obesity, which includes a Platycodon grandiflorum extract as an active ingredient and a method for preparing the extract with an improved anti-obesity effect. The extract shows an effect of inhibiting increases in body weight and fat mass caused by a high-fat diet for normalization, an increase in fasting blood glucose and a decrease in energy expenditure in a diet-induced obesity mouse model. Further, compared to an extract prepared by a conventional extraction method, the Platycodon grandiflorum extract shows a more excellent effect of inhibiting increases in body weight and fat mass, fasting blood glucose, and blood lipid and adipokine contents in experiments, resulting in an excellent anti-obesity effect. Therefore, the Platycodon grandiflorum extract prepared is expected to be useful for preventing obesity and treating obesity-related complications that can be caused by an increase in fat mass as well as obesity.

The invention belongs to the field of biomedicine and relates to the medical use of miR-574-5p, in particular to the use of miR-574-5p in the preparation of drugs for the prevention or treatment of diabetes and related diseases. The invention provides the use of miR-574-5p, recombinant vector or recombinant cell expressing miR-574-5p nucleic acid molecule in the preparation of drugs for the prevention or treatment of diabetes and related diseases. Also provided is the use of a reagent for detecting miR-574-5p or its activity expression level in serum or plasma in the preparation of a kit for the prediction and / or treatment effect and prognosis evaluation of diabetes and related diseases. The experiment of the present invention proves that miR-574-5p is highly expressed in human adipose tissue, and the expression level increases significantly with the differentiation of adipocytes; increasing miR-574-5p promotes adipocyte differentiation and resists insulin resistance caused by obesity; inhibits miR The expression of ‑574‑5p will aggravate obesity and insulin resistance; in people with similar BMI, the expression of miR‑574‑5p in the serum of people with impaired glucose tolerance and diabetes will be significantly reduced. miR‑574‑5p can be used to detect, prevent or treat diabetes and related diseases.

The invention discloses an application of LncRNA-063 in preparation of a preparation for promoting body energy metabolism and resisting obesity. The effect is exact, and the LncRNA-063 effectively promotes the energy metabolism of an organism by promoting the beige adipocytes to differentiate into the brown adipocytes, so that obesity is resisted; and the effects of reducing blood sugar and improving insulin sensitivity are achieved.

The present invention provides a peptide with an anti-obesity and / or anti-diabetic activity consisting of an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 2. The peptide of the present invention exhibits an excellent anti-obesity effect by inhibiting fat accumulation, reducing the sizes of adipocytes, and breaking down accumulated fat through an increase in the expression of lipolytic factors pHSL and AMPK-α1, and CGI-58, and furthermore, an excellent effect on diabetes by increasing an expression of adiponectin and AMPK which effectively reduce blood glucose and improves insulin resistance, increasing the expression of glucose transporter GLUT4, and increasing an expression of IRS-1, an insulin receptor signal transduction protein. The peptide of the present invention can be effectively used for the prevention or treatment of obesity and / or diabetes.

The invention relates to a food additive composition and a preparation method and application thereof, and solves the technical problem that the existing composition is not beneficial to human health and absorption. The food additive composition contains vanadium binding protein and 5-2,6-dihydroxy-4-(2,4,6-trihydroxyphenyl)benzene-1,2,3-trihydroxybenzene. The invention also provides a preparation method and application thereof. The method can be used in the field of preparation of anti-oxidation and anti-obesity food.

The invention discloses a phaseolus calcaratus extract and application of the phaseolus calcaratus extract in resisting obesity, and belongs to the technical field of weight-losing food. The phaseolus calcaratus extract prepared by a water extraction method has important influence on intestinal flora of high-fat diet mice, and the intestinal flora in the high-fat diet mice can be regulated and controlled by the phaseolus calcaratus extract, so that the body fat rate is reduced, and the body weight is controlled; meanwhile, a theoretical reference is provided for prevention and control and mechanism research of HFD-induced related diseases.

The invention provides a flavone skeleton transition derivative and a medical application thereof, and belongs to the technical field of medicines. Specifically, the invention relates to a compound asshown in a formula I, and the compound has anti-diabetes and anti-obesity effects. An experiment result of a DIO obese mouse model shows that the derivative as shown in the formula I can remarkably reduce the weight of a DIO obese mouse in a dose-dependent manner and remarkably reduce the waist fat volume rate of the obese mouse in a dose-dependent manner, and has a definite anti-obesity effect.On the other hand, the compound as shown in the formula I can significantly reduce fasting blood glucose of the DIO mouse in a dose-dependent manner, and significantly reduce plasma insulin level, total cholesterol, MDA, glycosylated hemoglobin and sugar tolerance of the model mouse in a dose-dependent manner, wherein the glycosylated hemoglobin can effectively reflect the blood glucose control condition of a diabetes patient in the past 1-2 months, is a gold standard for measuring blood glucose control, and has a remarkable anti-diabetes effect.

The object of the present invention is to provide an anti-obesity agent which contains a tea-derived component and which is safe and does not compromise the flavor of foods and beverages.According to the present invention, a safe and palatable anti-obesity agent can be provided by incorporating a benzotropolone ring-containing compound which has tea-derived, high inhibitory activities against lipase and alfa-glucosidase. The anti-obesity agent of the present invention does not compromise the flavor of foods and beverage, has palatability, and can be used in various use applications including foods and beverages intended for health enhancement such as reduction in triglycerides.

Described herein are inhibitors Transient Receptor Potential Canonical (TRPC) ion channels comprising TRPC4 protein and / or TRPC5 protein for use in combating obesity and other medical conditions including insulin resistance associated with Type II diabetes or development of Type II diabetes (pre-diabetes), metabolic syndrome, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Also disclosed is the use of the inhibitors for cosmetic purposes, such as cosmetic weight loss.

The invention provides a medicine for preventing and treating metabolic syndrome induced by saturated fatty acid. Experiments prove that the 2-bromohexadecanoic acid can inhibit endoplasmic reticulum stress, inflammatory response, apoptosis and insulin resistance caused by high saturated fatty acid diet, and can be used for preparing medicines for preventing and resisting metabolic syndromes caused by obesity or high fat diet.